Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encenicline Phase 3 in mild to moderate Alzheimer's disease
NCT01969136Phase 3Terminated
- Sponsor
- FORUM Pharmaceuticals
- Start
- Oct 2013
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of encenicline in Alzheimer's disease (AD) (3 arms), sponsored by FORUM Pharmaceuticals. Primary endpoints: Alzheimer's Disease Assessment Scale-Cognitive Subscale 13-item at Day 182, Clinical Dementia Rating Sum of the Boxes at Day 182 and 1 more. Started Oct 2013; status: terminated.
02
Drugs
encenicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01969136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01969136.